{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:19:38Z","timestamp":1791821978840,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010731","name":"Faculty of Medicine, Chiang Mai University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012304","name":"Johns Hopkins University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.apjo.2025.100176","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T23:28:43Z","timestamp":1740871723000},"page":"100176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Recurrent polypoidal lesions after achieving inactive polypoidal choroidal vasculopathy following 1-year fixed-dosing aflibercept treatments"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0426-7602","authenticated-orcid":false,"given":"Voraporn","family":"Chaikitmongkol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1436-568X","authenticated-orcid":false,"given":"Wantip","family":"Tadadoltip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0124-722X","authenticated-orcid":false,"given":"Direk","family":"Patikulsila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titipol","family":"Srisomboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanusnun","family":"Narongchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-0270","authenticated-orcid":false,"given":"Janejit","family":"Choovuthayakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-8694","authenticated-orcid":false,"given":"Nawat","family":"Watanachai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paradee","family":"Kunavisarut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apisara","family":"Sangkaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phit","family":"Upaphong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M.","family":"Bressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apjo.2025.100176_bib1","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100176_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","article-title":"Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians","volume":"53","author":"Wong","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.apjo.2025.100176_bib3","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/archopht.121.10.1392","article-title":"Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics","volume":"121","author":"Sho","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100176_bib4","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1167\/iovs.08-1803","article-title":"Prevalence and associated risk factors of age-related macular degeneration in an elderly Chinese population in Taiwan: the Shihpai eye study","volume":"49","author":"Chen","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.apjo.2025.100176_bib5","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/bjo.86.8.892","article-title":"Polypoidal choroidal vasculopathy in Chinese patients","volume":"86","author":"Kwok","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100176_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","article-title":"Idiopathic polypoidal choroidal vasculopathy (IPCV)","volume":"10","author":"Yannuzzi","year":"1990","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100176_bib7","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/01.APO.0000656992.00746.48","article-title":"Latest developments in polypoidal choroidal vasculopathy: epidemiology, etiology, diagnosis, and treatment","volume":"9","author":"Chaikitmongkol","year":"2020","journal-title":"Asia Pac J Ophthalmol (Philos"},{"key":"10.1016\/j.apjo.2025.100176_bib8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0002-9394(02)01404-6","article-title":"Polypoidal choroidal vasculopathy: natural history","volume":"133","author":"Uyama","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100176_bib9","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00417-015-2933-2","article-title":"The natural history of polypoidal choroidal vasculopathy: a multi-center series of untreated Asian patients","volume":"253","author":"Cheung","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100176_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3349\/ymj.2007.48.2.225","article-title":"Polypoidal choroidal vasculopathy in Korean patients with large submacular hemorrhage","volume":"48","author":"Yoon","year":"2007","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.apjo.2025.100176_bib11","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100176_bib12","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial","volume":"135","author":"Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100176_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101057","article-title":"A prospective study of treatment patterns and 1-year outcome of Asian age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"9","author":"Cheung","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.apjo.2025.100176_bib14","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.ophtha.2015.05.024","article-title":"One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy","volume":"122","author":"Yamamoto","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100176_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.oret.2021.03.012","article-title":"Timing of complete polypoidal regression following intravitreous aflibercept treatments in polypoidal choroidal vasculopathy","volume":"6","author":"Chaikitmongkol","year":"2022","journal-title":"Ophthalmol Retin"},{"key":"10.1016\/j.apjo.2025.100176_bib16","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/IAE.0b013e31816577cb","article-title":"Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy","volume":"28","author":"Akaza","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100176_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10384-010-0886-x","article-title":"Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy","volume":"55","author":"Akaza","year":"2011","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100176_bib18","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ajo.2012.09.020","article-title":"Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy","volume":"155","author":"Kang","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100176_bib19","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00417-015-3241-6","article-title":"Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy","volume":"254","author":"Kang","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100176_bib20","doi-asserted-by":"crossref","first-page":"21572","DOI":"10.1038\/s41598-021-00904-4","article-title":"Recurrence and visual prognostic factors of polypoidal choroidal vasculopathy: 5-year results","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.apjo.2025.100176_bib21","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ajo.2013.05.038","article-title":"Long-term visual outcome and prognostic factors after Intravitreal Ranibizumab injections for polypoidal choroidal vasculopathy","volume":"156","author":"Kang","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100176_bib22","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"Koh","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100176_bib23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/APO.0000000000000551","article-title":"Optical coherence tomography features for identifying posttreatment complete polypoidal regression in polypoidal choroidal vasculopathy","volume":"11","author":"Chaikitmongkol","year":"2022","journal-title":"Asia Pac J Ophthalmol (Philos)"},{"key":"10.1016\/j.apjo.2025.100176_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","article-title":"Pachychoroid disease","volume":"33","author":"Cheung","year":"2019","journal-title":"Eye"},{"key":"10.1016\/j.apjo.2025.100176_bib25","first-page":"379","article-title":"Impact of polyp regression on 2-year outcomes of intravitreal aflibercept injections: a treat-and-extend regimen for polypoidal choroidal vasculopathy","volume":"724","author":"Morizane-Hosokawa","year":"2018","journal-title":"Acta Med Okayama"},{"key":"10.1016\/j.apjo.2025.100176_bib26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ophtha.2022.09.013","article-title":"Progression of polypoidal lesions associated with exudative recurrence in polypoidal choroidal vasculopathy","volume":"130","author":"Bo","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100176_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10384-008-0582-2","article-title":"Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy","volume":"52","author":"Yamashiro","year":"2008","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100176_bib28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12886-018-0801-7","article-title":"Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1+\u2009PRN regimen","volume":"18","author":"Lai","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100176_bib29","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/bjophthalmol-2018-312419","article-title":"Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study","volume":"103","author":"Miyamoto","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100176_bib30","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/IAE.0000000000002384","article-title":"Posttreatment polyp regression and risk of massive submacular hemorrhage in eyes with polypoidal choroidal vasculopathy","volume":"40","author":"Cho","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100176_bib31","article-title":"Evolution of polypoidal lesions after treatment of polypoidal choroidal vasculopathy","volume":"2","author":"Tan","year":"2021","journal-title":"Ophthalmol Sci"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216209892500043X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216209892500043X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T09:00:05Z","timestamp":1742288405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S216209892500043X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S216209892500043X"],"URL":"https:\/\/doi.org\/10.1016\/j.apjo.2025.100176","relation":{},"ISSN":["2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrent polypoidal lesions after achieving inactive polypoidal choroidal vasculopathy following 1-year fixed-dosing aflibercept treatments","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjo.2025.100176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of Asia-Pacific Academy of Ophthalmology and Academy of Asia-Pacific Professors of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100176"}}